Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target of $3.00. The company’s shares closed last Friday ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monopar Therapeutics Inc (MNPR – Research Report) and Nektar Therapeutics (NKTR – Research ...

(Image Credits: Pixabay) Immuneel Therapeutics on Monday launched Qartemi, a CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL). According to the company’s statement, it is ...

A Quick Take On Odyssey Therapeutics, Inc. Odyssey Therapeutics, Inc. (ODTX) has filed to raise $100 million in an IPO of its ordinary shares, according to SEC S-1 registration information.

This page features the latest news about the Kyverna Therapeutics stock. Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms ...

Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and ...

CAMBRIDGE, England & BOSTON, January 13, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary ...

This page features the latest news about the Century Therapeutics stock. Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B ...

Our round-up of recent biotech financings features a strong first round for City Therapeutics, a new RNAi venture led by biotech doyen John Maraganore, and additional cash for Purespring ...